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Effects of ICAM-1 antisense oligonucleotide on the renal tubu- molecule fibrinogen, and the matrix factor hyaluronan
lointerstitium in mice with unilateral ureteral obstruction. [1–5]. ICAM-1 plays an important role in inflammatory
Background. To extend our previous study of the therapy processes and in the T-cell–mediated immune responseof the renal lesions of unilateral ureteral obstruction (UUO)
system. In normal conditions, ICAM-1 is constitutivelyin mice by an inhibitor of intercellular adhesion molecule-1
expressed by capillary endothelial cells of kidney, and(ICAM-1), we investigated the blocking effects of ICAM-1
antisense oligonucleotides (ASONs) on the ICAM-1 expres- ICAM-1 expresses at basal or low levels on the surface
sion in mouse kidney. of glomerular mesangial cells and renal tubular epithelial
Methods. First, ICAM-1 ASON was transducted into mouse cells (TECs) [6]. However, in response to stimuli fromrenal tubular epithelial cells to investigate the effects of
inflammatory mediators such as cytokines, the expres-ICAM-1 ASON in vitro. Second, fluorescein isothiocyanate
sion of ICAM-1 can be markedly up-regulated in mesan-(FITC)-labeled ICAM-1 ASON was injected intravenously to
determine the distribution of the ASON in vivo. Third, the gial and epithelial cells of the kidney [7, 8]. Although
expression of ICAM-1 in kidney and the changes of renal ICAM-1 by itself probably does not elicit an inflamma-
morphology were observed to investigate the therapeutic ef-
tory response and more likely functions as an inflamma-fects of ICAM-1 ASON on the UUO mice in vivo.
tion-enhancing molecule, increased ICAM-1 expressionResults. The expressions of ICAM-1 in the epithelial cells
induced by interleukin-1b were inhibited by ICAM-1 ASON of the cells has been implicated in a variety of disorders
at the dosages of 100 and 200 nmol/L. Twenty-four hours after characterized by local inflammation in kidney [9].
an introvenous injection with FITC-labeled ICAM-1 ASON, Many studies have demonstrated that antibodies against
the highest level of fluorescein was detected within the proximal
ICAM-1 have beneficial effects in animal models of in-tubules in mouse kidney. Results of immunohistology and
flammatory kidney diseases, and preliminary clinical dataNorthern blot showed that the ICAM-1 expression was mark-
edly reduced in the obstructed kidney after treatment with have also shown that the ICAM-1 monoclonal antibody
ICAM-1 ASON. The ASON also alleviated the infiltration of has good therapeutic effects in renal allografts [10–12].
inflammatory cells and accumulation of the extracellular matrix In our previous study, we observed that the expression
in the tubulointerstitium of UUO mice without apparent side
of ICAM-1 and the infiltration of inflammatory cells ineffects.
the renal tubulointerstitium decreased after the adminis-Conclusion. Our data demonstrate that ICAM-1 ASON is
taken up primarily by the proximal tubular cells of mouse tration of an ICAM-1 monoclonal antibody in a mouse
kidney. ICAM-1 ASON can selectively inhibit the ICAM-1 model of unilateral ureteral obstruction (UUO) [13].
expression of the renal tubular cells both in vitro and in vivo. Because antisense oligonucleotides (ASONs) provide
a novel strategy to inhibit RNA transcription and thereby
the synthesis of the protein, ASONs as therapeutic agents
The intercellular adhesion molecule-1 (ICAM-1) is a have been developed during the past years. Recently,
transmembrane glycoprotein that belongs to the Ig super- ASONs that inhibit the expression of ICAM-1 on either
gene family. Its ligands are the membrane-bound integ- human or murine endothelial cells were identified [14, 15].
rin receptor lymphocyte function-associated antigen-1 The murine-specific ASON was shown to selectively in-
(LFA-1) and Mac-1 on leukocytes, CD43, the soluble hibit the expression of ICAM-1 and infiltration of leuko-
cytes in lesions of a colitis model or a transplantation
model in a sequence-specific manner [16, 17].Key words: intercellular adhesion molecule, inflammation, obstructed
kidney, proximal tubule cells, extracellular matrix. To extend our previous study of the therapy of the
renal lesions of UUO mice by inhibitors of ICAM-1, weReceived for publication December 1, 1998
investigated the blocking effects of ICAM-1 ASONs onand in revised form June 14, 1999
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after intravenous injection, and the therapeutic effects controls for immunostaining consisted of equivalent con-
centration of an irrelevant murine monoclonal antibodyof ICAM-1 ASONs on the renal injury of UUO mice.
and the cells without stimulation of IL-1b.
METHODS Distribution of oligonucleotide in mouse in vivo
Oligonucleotides synthesis Studies were performed in female NIH mice (mean
weight 31 6 3.6 g) purchased from the animal centerPhosphorothioate oligonucleotides were synthesized
by Cybersyn Inc. (Lenni, PA, USA). The sequences of of the Chinese PLA General Hospital. FITC-labeled
oligonucleotides were given to the mice by intravenousthe oligonucleotides used in this study have been pre-
viously described [16]: mouse ICAM-1 ASON, 59-TGCA injection via the tail vein at the dose of 10 mg/kg. The
mice were sacrificed at 24 hours after injection of theTCCCCCAGGCCACCAT-39, and control oligonucleo-
tide, 59-TCGCATCGACCCGCCCACTA-39. The con- oligonucleotides. Kidney, liver, lung, and spleen were
frozen in liquid nitrogen, and cryosections were pre-trol oligonucleotide has the same base composition as
the ICAM-1 anitsense oligonucleotide but in a different pared. The distribution of FITC-labeled oligonucleotide
in the tissues was determined under a fluorescent micro-sequence. All of the oligonucleotides were purified by
reverse-phase high-performance liquid chromatography scope (Nikon, Tokyo, Japan).
(HPLC). For some studies, parts of oligonucleotides
Induction of unilateral ureteral obstructionwere labeled with fluorescein isothiocyanate (FITC) at
the 59-amine. Female NIH mice were anesthetized and underwent
left proximal ureteral ligation via a midline abdominal
Primary culture of mouse renal tubular epithelial cells incision. After the UUO surgery, the mice were divided
into three groups. Group A was treated with ICAM-1Primary mouse renal TECs were generated following
the method described by Wuthrich et al [18]. Briefly, ASON, which was injected intravenously at the dosage
of 1 mg/kg/day every other day for one week. Group Bsingle cortical tubular cell suspensions of freshly dissected
kidney cortices from normal NIH mice were prepared by was treated with the control oligonucleotide in the same
way, and group C was injected with normal saline solu-collagenase dispersion, sequential sieving through steel
meshes, and washing in RPMI 1640 medium (GIBCO tion only as a blank control. All of the mice were sacri-
ficed at the seventh day. The weights of the whole body,BRL, Grand Island, NY, USA). TECs were grown to
subconfluence on gelatin-coated flasks for six days in liver, spleen, and kidney were recorded, and blood sam-
ples were obtained for measurement of blood urea nitro-RPMI 1640 medium supplemented with 10% fetal calf
serum (FCS; GIBCO BRL). The primary TECs were gen (BUN), serum creatinine (Cr), and glutamic pyruvic
transaminase (GPT). The expression of ICAM-1 proteindigested by 0.2% pepsin/ethylenediaminetetraacetic acid
buffer (EDTA; GIBCO BRL) and planted to another and the number of Mac-1–positive cells were measured
by immunohistochemical staining. The pathologicalflask for growing. The identified secondary TECs were
used in the following experiments. changes of the obstructed kidney were analyzed by a
computer imaging system. The total RNA of renal tissue
Oligonucleotides treatment of tubular epithelial cells was extracted for analysis of the ICAM-1 mRNA by
Northern blotting.The cell transfection reagent DOTAP was purchased
from Boehringer Mannheim (Mannheim, Germany). For
Immunohistological study of ICAM-1 and Mac-1TEC transfection, oligonucleotides were sterilized by
expressions in UUO micecentrifugation through 0.2 mm centrex cellulose acetate
filters and diluted to a concentration of 0.1 mg/mL in Renal samples from the obstructed kidney of the UUO
mice were frozen in OCT embedding medium (Miles20 mmol/L HEPES buffer (pH 7.4). In this study, the
DOTAP/oligonucleotides mixture was prepared at the Inc., IN, USA). Four micrometer cryosections were incu-
bated with 5 mg/mL of rat antimouse ICAM-1 mono-ratio of 1 mg oligonucleotide per 1 mL DOTAP. Trans-
fected TECs were incubated for an additional four hours clonal antibody YN1/1.7.4, with 15 mg/mL of Mac-1 anti-
body (Pharmingen, San Diego, CA, USA). The slidesat 378C and were then incubated with or without interleu-
kin-1b (IL-1b; 10 m/mL) for 16 hours. were incubated with horseradish peroxidase-labeled rab-
bit antirat IgG, which was developed and examined under
Intercellular adhesion molecule-1 assay of tubular light microscope.
epithelial cells
Quantitative analysis of renal pathology in theThe ICAM-1 expression on the TEC surface was deter-
obstructed kidneymined by immunocytochemical staining. ICAM-1 mono-
clonal antibody YN1/1,7,4 (1 mg/mL) was a gift from Dr. The 2 mm paraffin sections from obstructed kidneys
of the UUO mice were stained with periodic acid-SchiffMatsuda (Juntendo University, Tokyo, Japan). Negative
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and Masson. The area of the dilated tubules and the rela- RESULTS
tive area of interstitium in the sections were evaluated Effects of ICAM-1 antisense oligonucleotide on the
by a computer image system with software of VIGP-2M ICAM-1 expression of tubular epithelial cells
Image/Graphics/Vision Video View series (CAS-DH induced by IL-1b
Co., HZ Image & Vision Inc., Beijing, China). Infiltrating
It has been demonstrated that ICAM-1 expressioninflammatory cells were counted using an eyepiece grati-
of cultured epithelial cells surface was increased aftercule (Olympus, Tokyo, Japan) at a magnification of 3400
stimulation of IL-1b [8, 20]. In our study, the resultsand were quantitated as cells per unit area (0.0625 mm2)
showed that ICAM-1 expression of TECs, which wasof the tubulointerstitium. All of these data were ex-
transfected with 100 or 200 nmol/L ICAM-1 ASONpressed as the mean values of 5 to 10 fields of the tubu-
through liposome-DOTAP, was significantly decreasedlointerstitium in each section.
compared with that of TECs transfected with control
Isolation of RNA of tubular epithelial cells and oligonucleotide (Fig. 1). The control oligonucleotide had
kidney tissue no effect on the ICAM-1 expression of TECs compared
with the blank control of transfection buffer. The resultsTotal cellular RNA was isolated from confluent mono-
also indicated that there was no inhibition of ICAM-1layers of transfected TECs using TRIZOL reagent
expression on TECs if the transfection of ICAM-1(GIBCO BRL). The kidney cortex tissue was minced and
ASON was performed without DOTAP. We comparedhomogenized in 5.5 mol/L guanidinium isothiocyanate
the effects of ICAM-1 ASON transfection with or with-citrate buffer, and the total tissue RNA was isolated by
out DOTAP. We found that the uptake of ICAM-1a cesium chloride gradient centrifugation. The total RNA
ASON by cultured TECs was significantly increasedwas quantitated with ultraviolet spectrophotometry.
when transfected with DOTAP (75.2 6 8.3% vs. 16.6 6
RT-PCR and preparation of the mouse ICAM-1 4.8%). Northern blot analysis showed that total cellular
cDNA probe mRNA levels of ICAM-1 from TECs transfected with
The ICAM-1 primers were designed from the se- ICAM-1 ASON were significantly decreased compared
quence of the mouse gene [19]: 59-CAACTGGAAGCT with that of the control sample. Representative autora-
GTTTGAGCTG-39 (sense) and 59-GTGTTCACAGT diograms for ICAM-1 mRNA expression are shown in
CTTGC TCCAT-39 (antisense) to yield a 1567 bp prod- Figure 2.
uct. Polymerase chain reaction (PCR) was performed
with a DNA Thermal Cycler (MJ Inc., Watertown, MA, Distribution of ICAM-1 antisense oligonucleotides in
USA) using the following program: 948C for one minute, mouse in vivo
608C for one minute, and 728C for two minutes. Amplifi- Previous animal studies have demonstrated that fol-
cations were carried out for 30 cycles. PCR products were lowing systemic administration, phosphorothioate oligo-
analyzed by electrophoresis through a 1.0% agarose gel nucleotides are primarily excreted by the kidney and
with ethidium bromide (0.5 mg/mL). A 1567 bp template that renal tissue levels of the oligonucleotides exceed
for the ICAM-1 probe was prepared by PCR of renal that of other organs. Within the kidney, the oligonucleo-
cortex cDNA. The PCR product was isolated from low tides are taken up primarily by proximal tubular cells,
melting point agarose and was purified using a Gene- with much lower uptake by cells in other segments of
clean kit (Cambridge Biosystems, Cambridge, UK).
the nephron [21]. To obtain information about the distri-
bution of ICAM-1 ASON in mice, we injected the FITC-Northern blotting analysis
labeled ICAM-1 ASON via tail vein at 10 mg/kg intoTotal RNA was separated, transferred to a nylon mem-
either normal mice or mice with UUO operation for 16brane (Bio-Rad, Hercules, CA, USA), and cross-linked
hours. The mice were sacrificed at the 24th hour afterby ultraviolet irradiation (UVP, Cambridge, UK). After
injection, and the location of the oligonucleotide wasbeing prehybridized, the blots were hybridized with
observed in the cryostat sections of the kidney, liver,mouse ICAM-1 cDNA probe labeled with [a-32P]dCTP
lung, and spleen. In the normal mice, the ICAM-1 ASONusing random primed DNA labeling kit (Boehringer
localized predominantly to the renal proximal tubularMannheim, Germany) at 658C for 24 hours. Autoradiog-
cells. The fluorescein was not detected within the glomer-raphy was performed at 2708C using intensifying screens.
uli and the distal tubular cells (Fig. 3). Much lower levels
Statistical analysis of FITC-labeled ICAM-1 ASON were found in the liver,
lung, and spleen of the mice. In UUO mice, the distribu-The values of the groups were expressed as means 6
tion and level of the oligonucleotide in the obstructedsd. Data were analyzed for statistical significance by
kidney were not different from those of the contralateralStudent’s t-test or Mann–Whitney U-test, and a P value
,0.05 was considered significant. unobstructed kidney.
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Fig. 1. Immunocytochemical studies for in-
tercellular adhesion molecule-1 (ICAM-1) ex-
pression in cultured tubular epithelial cells.
(A) Immunostaining for anti–ICAM-1 anti-
body in the cultured tubular epithelial cells
treated by the cell transfection solution with-
out any oligonucleotides (3400). (B) Only
weak immunostaining was observed in the cul-
tured tubular epithelial cells after treatment
with 100 nmol/L ICAM-1 antisense oligonu-
cleotide (3400). (C) Intense immunostaining
was found in the cultured tubular epithelial
cells that were treated by 100 nmol/L control
oligonucleotide (3400). (D) There was not
marked immunostaining for anti–ICAM-1 an-
tibody in the normal cultured tubular epithe-
lial cells without stimulation of IL-1b (3400).
All of the cells of group A, B, and C were
stimulated by IL-1b at the concentration of
10 U/mL.
Fig. 4. Immunohistochemical studies
for the expression of ICAM-1 and
Mac-1 in the obstructed kidney of
UUO mice. (A) Immunostaining for
anti–ICAM-1 antibody in the mice
treated with the normal saline solution
(3132). (B) Only weak and local im-
munostaining was observed in the mice
treated with ICAM-1 antisense oligo-
nucleotide at dosage of 1 mg/kg (3132).
(C) Intense and diffuse immunostain-
ing was found in the mice treated by
control oligonucleotide at 1 mg/kg
(3132). (D) The negative control (re-
placing anti–ICAM-1 antibody with ir-
relevant antibody) of the obstructed
kidney (3132). (E) Immunostaining
for anti–Mac-1 antibody in the mice
treated with normal saline solution
(3132). (F ) Only weak and local im-
munostaining of anti–Mac-1 antibody
was observed in the mice treated with
ICAM-1 antisense oligonucleotide at
dosage of 1 mg/kg (3132).
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Fig. 2. Northern blot analysis of total cellular RNA from the tubular
epithelial cells. The top of the figure shows the blots of IL-1b stimulating
cells treated by 100 nmol/L ICAM-1 antisense oligonucleotide (lane 2)
and the cells treated by 100 nmol/L control oligonucleotide (lane 3),
Fig. 5. Northern blot analysis of total RNA from the obstructed kidneyand the cells treated by transfection solution without any oligonucleo-
of UUO mice. The top of the figure shows the blots of the obstructedtides (lane 4). Lane 1 shows the blot of RNA isolated from cultured
kidney that were treated by 1 mg/kg ICAM-1 antisense oligonucleotidecells that had not been treated with IL-1b. At the bottom of the figure
(lane 2), the obstructed kidney treated by control oligonucleotide (lanewere the intact 28s and 18s ribosomal bands.
3), and the obstructed kidney treated with normal saline solution only
(lane 4). Lane 1 shows the blot of RNA isolated from the kidney of
sham operated mice. At the bottom of the figure are the intact 28S and
18S ribosomal bands.
Therapeutic effects of ICAM-1 ASON on renal
pathological changes in UUO mice
On the seventh day after UUO operation, marked
inflammatory cell infiltration, dilated tubules, and extra-
cellular matrix accumulation in the tubulointerstitium
were found in the obstructed kidneys of the mice. The
number of the inflammatory cells and the degree of the
matrix accumulation were alleviated after treatment withFig. 3. Location of FITC-labeled ICAM-1 antisense oligonucleotide in
the kidney of mice in vivo. The fluorescein was localized predominantly ICAM-1 ASON in the obstructed kidney. However, there
to the renal proximal tubular cells at 24 hours after injection of FITC- was no therapeutic effect of ICAM-1 ASON on the dila-
labeled ICAM-1 antisense oligonucleotide at 10 mg/kg.
tion of the tubules (Fig. 6). The results of quantitative
pathological assay are shown in Table 1.
Effects of ICAM-1 antisense oligonucleotide on Side effects of ICAM-1 ASON in UUO mice
ICAM-1 expression in UUO mice
Phosphorothioate oligonucleotides may result in sple-
Our previous study demonstrated that there is an in- nomegaly, lymphoid hyperplasia, and mild liver or kid-
tense staining of ICAM-1 and a number of Mac-1– ney dysfunction in animals [22]. In the present study, the
positive staining cells in the peritubular interstitial space weights of kidney, liver, spleen, the serum chemistry
of the obstructed kidney seven days after UUO opera-
parameters of liver and kidney functions as well as the
tion in mice [13]. In the current study, the immunohisto-
urine protein of the mice treated with ICAM-1 ASONlogical data showed that the ICAM-1 expression and the
were compared with those changes of the control oligo-number of Mac-1–positive cells were markedly de-
nucleotide-treated and normal saline-treated mice. Thecreased in the renal tubulointerstitium of the obstructed
results showed that there were no apparent clinical signskidney after treatment with ICAM-1 ASON (Fig. 4).
of toxicity in mice treated with 1 mg/kg ICAM-1 ASONThe control oligonucleotide had no effect on ICAM-1
or control oligonucleotide. There were no statisticallyexpression and the number of Mac-1–positive cells in
significant changes in the organ weights and chemistrythe obstructed kidney of UUO mice. By Northern blot
parameters (GPT, BUN, Cr, and urine protein) betweenanalysis, the expression of ICAM-1 mRNA in the renal
the mice treated with ICAM-1 ASON, control oligonu-cortex was also decreased after treatment with ICAM-1
ASON (Fig. 5). cleotide, and the normal saline solution.
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Fig. 6. Renal morphological
changes of the UUO mice. Kid-
neys from UUO mice were re-
moved and formalin fixed. Two
micrometer-thick paraffin sec-
tions were stained with periodic
acid-Schiff. (A) UUO mice were
treated with 1 mg/kg ICAM-1
antisense oligonucleotide for
seven days (3132). (B) UUO
mice were treated by control
oligonucleotides at 1 mg/kg for
seven days (3132). (C) UUO
mice were treated with normal
saline solution only (3132).
Table 1. Quantitative analysis of renal pathological changes
Inf. cell number A. of tubules RA. of interstitium
Group N cells/mm2 lm2 %
Antisense ODN 7 110 614a 1979.36241.4 7.4760.88a
Control ODN 8 270 613 1980.76316.5 25.38 63.98
Saline solution 6 276 624 1816.06180.4 28.08 64.02
Abbreviations are: ODN, oligonucleotide; Inf., inflammatory cells; A., area; RA., relative area.
a P , 0.01, compared with group of control ODN and group of saline
DISCUSSION scopic observations showed that injected oligonucleotide
did not merely accumulate in the brush border or lyso-The use of ASONs to block gene expression was intro-
somal compartment in proximal tubular cells, implyingduced by Zamecnik and Stephenson [23]. Because of
that they were not totally degenerated after being phago-the specificity of Watson-Crick base pair hybridization,
cytosed by the proximal tubule [28]. These results suggestASONs have been used extensively in attempts to inhibit
that the renal proximal tubule is a good target of anti-expressions of distinct genes both in vitro and in vivo.
sense therapy.Although the precise mechanism of action has not been
Data from previous animal studies on the pharmaco-clarified, ASONs offer considerable promise with the de-
kinetics and tissue distribution of oligonucleotide havevelopment of novel molecular therapeutic agents against
suggested that the kidney may be an ideal target fordiseases including AIDS, cancer, and inflammatory dis-
application of ASONs [21, 28, 29]. Following systemicorders [24]. Several investigators have reported the ap-
administration to both mice and rabbits, radiolabeledplications of ASON to kidney cell lines in vitro. ASON
oligonucleotides were excreted primarily in the urine.targeting the mRNA of rat kidney sodium phosphate
Tissue levels of oligonucleotide attained in murine kid-cotransporter NaPi-2 protein reduced the rate of phos-
neys were markedly higher than those in all other organsphate uptake into the tubular cell brush border mem-
[29, 30]. Similar results are gained in our current studybrane vesicles [25]. Glomerular mesangial cells exposed
using the FITC-labeled oligonucleotide.to ASONs of proliferating cell nuclear antigen (PCNA)
Recently, researchers have examined the effects ofand Ki-67 had decreased levels of PCNA and Ki-67
ASONs in experimental animals in vivo. SpontaneouslymRNA and a decreased rate of cell proliferation [26].
hypertensive rats injected with ASON targeting againstOur current study provides evidence that ICAM-1 ex-
either angiotensinogen or angiotensin II type I receptorpression of the cultured renal TECs is induced by IL-1b,
mRNA had a significant reduction in systemic blood pres-which is interrupted by ICAM-1 ASON.
sure [31]. Haller et al reported the suppression of ICAM-1Rappaport et al studied the fate of 32P-labeled oligonu-
expression and the attenuation of ischemia/reperfusioncleotides after intravenous injection [27]. The labeled
injury by administration of rat ICAM-1 ASON [32].oligonucleotides were predominantly localized in kidney
Other authors demonstrated that the anti-transformingand liver and were detected in the proximal tubular cells
within 30 minutes after injection. The electron micro- growth factor-b (TGF-b) ASONs inhibited TGF-b ex-
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pression and glomerular extracellular matrix accumula- UUO mice after treatment with ICAM-1 ASON at the
tion in Thy1 glomerulonephritis [33]. dosage of 1 mg/kg.
Ureterally obstructed mice are a cell-mediated model In conclusion, our studies demonstrate that ICAM-1
for progressive nonimmune renal injury involving macro- ASON has a blocking effect on the infiltration of Mac-1–
phages, up-regulated TGF-b expression, extracellular positive cells and the extracellular matrix accumulation
matrix accumulation, and eventual scarring of the tubulo- in the early stages of the injured renal interstitium of
interstitial compartment [34]. Up-regulation of ICAM-1 UUO mice. The therapeutic effect of ICAM-1 ASON
expression on proximal tubules and the cortical intersti- may be owed to its inhibitive effects on ICAM-1 expres-
tium has been reported in this model. Using immunohis- sion of the renal TECs because the antisense is predomi-
tochemistry and in situ hybridization, Ricardo et al have nantly taken up by renal proximal TECs after intrave-
found that ICAM-1 and ICAM-1 mRNA transcription nous injection, and the ICAM-1 expression of renal
localized to the renal tubules and interstitium of the tubules is inhibited by the ICAM-1 ASON in vitro and
renal cortex of obstructed kidney [35]. Our previous in vivo. The treatment with ICAM-1 ASON is safe for
study shows that administration of anti–ICAM-1 anti- the UUO mice at the therapeutic dosage.
body to mice resulted in significant reductions in infil-
trating leukocytes and tubular epithelial damage, as as- ACKNOWLEDGMENTS
sessed by light microscopy [13].
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